CURRICULUM VITAE

EMERITUS PROF. DR. LIAM CHONG KIN

Professor Dr. Liam Chong Kin, is a Professor of Medicine and Senior Consultant Respiratory Medicine Physician working in the University Malaya Medical Centre/Faculty of Medicine, University of Malaya (UM), Kuala Lumpur, Malaysia and in the UM Specialist Centre. He was the President of the Malaysian Thoracic Society for 4 terms from 2001 to 2009 after which he remained as a council member of the Malaysian Thoracic Society till 2015. He is a council member of the Asian Pacific Society of Respirology since 2002. He is a fellow of the American College of Chest Physicians (since 1997), Royal College of Physicians (London) (since 1999) and the Asian Pacific Society of Respirology (since 2012). He is also an active member of the International Association for the Study of Lung Cancer (IASLC) and the European Respiratory Society. He was the organising chairman for the 8th Congress of the Asian Pacific Society of Respirology that was held in Petaling Jaya from 1-4 December 2003. He chaired the scientific programme committee for the International Union Against Tuberculosis and Lung Disease - Asia Pacific Region Conference that was held in Kuala Lumpur from 2-5 August 2007. He was the organising chairman for the 2014 IASLC Asia Pacific Lung Cancer Conference held in Kuala Lumpur from 6-8 November 2014. He was a member of the scientific committee for the biennial Asia Pacific Lung Cancer Conferences held in various countries including Hyderabad (India), Seoul (South Korea), Fukuoka (Japan) and Chiangmai (Thailand).  He was the advisor to the local organising committee for the 20th Congress of the Asian Pacific Society of Respirology held in Kuala Lumpur from 3-6 December 2015. He headed the Lung Cancer Assembly of the Asian Pacific Society of Respirology from 2015 to 2019. His areas of clinical interest include the up-to-date treatment of lung cancer, chronic obstructive pulmonary disease (COPD), and bronchial asthma. His research interests include molecular genotyping, novel molecular targeted therapies and immunotherapy for lung cancer, novel therapies for COPD and b2-adrenoceptor genetic polymorphisms in bronchial asthma. He has been an invited speaker for a wide range of topics in Respiratory Medicine, especially in lung cancer, COPD, asthma and pneumonia at international and regional conferences such as the World Conference on Lung Cancer and the Asian Pacific Society of Respirology annual congresses; as well as national scientific conferences and symposia.  He has published 193 scientific papers in peer-reviewed medical journals and is the author or co-author of 305 papers presented at national, regional and international scientific meetings.
PROFILE
Address
Department of Medicine, Faculty of Medicine Office of The, University of Malaya, 50603 Kuala Lumpur, Malaysia
Website
umexpert.um.edu.my/liamck
CONTACT
Telephone
+603-79493207
Email
liamck
liamck
RESEARCH ID
QR Code
Orcid id
https://orcid.org/0000-0002-3639-9231
Researcher id
AAC-8475-2022
Scopus id
0000-0002-3639-9231
ACADEMIC QUALIFICATION
Expert Training, Medicine, Royal College of Physicians of Edinburgh, United Kingdom, 1985
Bachelor Degree, Medicine and Surgery, Universiti Malaya (UM), 1980
PROFESSIONAL MEMBERSHIP/ FELLOWSHIP
WORKING EXPERIENCE
RESEARCH ACHIEVEMENT
Research Areas
A survey on COPD diagnosis among Primary Care Physicians in Malaysia., LUX-Lung 3: A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first- line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation, Recognise Asthma and Link to Symptoms and Experience (REALISE) Asia Working Group study: Identification of Attitudinal Clusters in Patients with Asthma, A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 micrograms Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy (AMGEN) , An Open Label, Randomised, Parallel Group, Multicentre, Phase III Study to Assess Efficacy, Safety and Tolerability of Gefitinib (IRESSA ) (250mg tablet) Versus Carboplatin / Paclitaxel Doublet Chemotherapy as First- Line Treatment in Selected Patients with Advanced (Stage IIIB or IV) Non- Small Cell Lung Cancer (NSCLC) in Asia (Iressa Pan-Asia Study - IPASS) , Distribution of IL-18 single nucleotide polymorphisms compared in non-asthmatics and asthmatics, Epidermal Growth Factor Receptor Mutations in Non- Small Cell Lung Cancer in Malaysian Patients, A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of CNTO 6785 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (1 Nov 2013 � 18 March 2015), Molecular analysis of selected genes among Malaysian asthmatics, Association of Interleukin-13 (IL-13) Gene Polymorphisms with Plasma IgE Levels and IL-13 Production in Malaysian Asthmatics, Treatment Of Latent TB infection - Identified By Tuberculin Skin Test/ QuantiFERON-Gold Test In Individuals With High Risk of Disease Reactivation, Is Effective In Controlling Tuberculosis In Malaysia, Epidemiological study of soil-transmitted helminthes infection and prevalence of asthma among the Orang Asli in Malaysia, ENSURE study - A multiple center, open-label, randomized phase III study to evaluate the efficacy and safety of Erlotinib (Tarceva®) versus gemcitabine/cisplatin as the first-line treatment for stage IIIB/IV non-small cell lung cancer (NSCLC) patients with mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) in their tumors, Asthma Control and Adherence in Asthma Patients on Maintenance Treatment in Asia, Study MK 3475-042: A Randomized, Open Label, Phase Ill Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Na'ive Subjects with PD-Ll Positive Advanced or Metastatic Non-Small Cell Lung Cancer , A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare MSC2156119J Combined with Gefitinib Versus Chemotherapy as Second- line Treatment in Subjects with MET Positive, Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance to First-line Gefitinib , Epidermal growth factor receptor mutations in squamous cell carcinoma of the lung, Budget Impact Analysis (BIA) to assess the affordability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment for EGFR mutation positive (EGFR+) non-small cell lung cancers, Discrepancy between patient-perception and guideline-defined asthma control in Asia: A survey of over 2400 patients, Detection of EML4-ALK in lung adenocarcinoma with immunohistochemistry and Fluorescent-in-situ hybridization technique, Treatment Outcome Of Malaysian Patients With Advanced Lung Adenocarcinoma, Outcome of First-line Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) and First-line Chemotherapy in Advanced Lung Adenocarcinoma
H Index: 32.00
Total Journal Publication: 43
Sum of Citation: 6594.00
Books: 1
Proceedings: 0
Research Grants: More than RM Fifty seven thousand one hundred and twenty
liamck